This database contains 523 studies, archived under the term: "Alzheimer’s Disease"
Click here to filter this large number of results.
Do nurse-led skill training interventions affect informal caregivers’ out-of-pocket expenditures?
Van Houtven, C. H.,
Thorpe, J. M.,
Chestnutt, D.,
Molloy, M.,
Boling, J. C.,
Davis, L. L.
Purpose Of the Study: This paper is a report of a study of the Assistance, Support, and Self-health Initiated through Skill Training (ASSIST) randomized control trial. The aim of this paper is to understand whether participating in ASSIST significantly changed the out-of-pocket (OOP) costs for family caregivers of Alzheimer’s disease (AD) or Parkinson’s disease (PD) […]
Effects of SolCos model-based individual reminiscence on older adults with mild to moderate dementia due to Alzheimer disease: a pilot study
Van Bogaert, Peter,
Van Grinsven, Regine,
Tolson, Debbie,
Wouters, Kristien,
Engelborghs, Sebastiaan,
Van der Mussele, Stefan
Objective: To examine effects of individual thematically-based reminiscence sessions based on the SolCos model for older adults with dementia because of Alzheimer disease (AD) as a pilot study.; Background: Reminiscence activities are popular within nursing homes and generally considered to be enjoyable and helpful, however, there is a paucity of robust data demonstrating therapeutic impact. […]
Detection of disease-associated α-synuclein in the cerebrospinal fluid: a feasibility study
Unterberger, Ursula,
Lachmann, Ingolf,
Voigtländer, Till,
Pirker, Walter,
Berghoff, Anna S.,
Flach, Katharina,
Wagner, Uta,
Geneste, Aline,
Perret-Liaudet, Armand,
Kovacs, Gabor G.
With the aim to evaluate the significance and reliability of detecting disease-specific α-synuclein in the cerebrospinal fluid (CSF) we developed an ELISA and bead-assay. We used a commercial antibody (5G4) that does not bind to the physiological monomeric form of α-synuclein, but is highly specific for the disease-associated forms, including high molecular weight fraction of […]
Prevalence of anosognosia in Alzheimer’s disease
Turró-Garriga, Oriol,
Conde-Sala, Josep Lluís,
Reñé-Ramírez, Ramón,
López-Pousa, Secundino,
Gascón-Bayarri, Jordi,
Garre-Olmo, Josep
Background and Objective: Anosognosia is a disorder that affects the clinical presentation of Alzheimer’s disease (AD), increasing in frequency with the evolution of AD. The objective was to determine the prevalence of anosognosia and analyze the associated factors and predictors.; Patients and Method: Multicenter transversal and observational study of 345 AD patients. Anosognosia was assessed […]
Study of the voxel-based specific regional analysis system for Alzheimer’s disease imaging sequence after magnetic resonance apparatus replacement
Tsukagoshi, Yuki,
Kanai, Yoshihiro,
Yasui, Gou,
Abe, Yuuji,
Maemura, Keisuke,
Nakazawa, Masaki,
Yamaji, Yuugo,
Mihara, Ban
In our institute, an MR apparatus, MAGNETOM VISION (Siemens) was replaced by ECHELON Vega (HITACHI). Z-score data acquired by MPRAGE (VISION) was compared with those by radio frequency-spoiled steady-state acquisition with rewinded gradient echo (RSSG) and gradient echo inversion recovery (GEIR) (ECHELON). For this study, ten normal volunteers were recruited and their data ware obtained […]
Implications of a longitudinal cognitive intervention program in mild Alzheimer’s disease
The implications of a longitudinal (5 years) intervention program in a mild Alzheimer’s disease (mAD) patient targeting mainly the language deficits were investigated. The program had 2 parts: the intensive one included training strategies and tasks that enhanced his impairments (memory, naming, comprehension), and the second one (the next 4 years), without guidelines or teaching. […]
Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer’s disease
Trzepacz, Paula T.,
Cummings, Jeffrey,
Konechnik, Thomas,
Forrester, Tammy D.,
Chang, Curtis,
Dennehy, Ellen B.,
Willis, Brian A.,
Shuler, Catherine,
Tabas, Linda B.,
Lyketsos, Constantine
Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer’s disease (AD).; Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory […]
Treatment of sleep apnoea syndrome decreases cognitive decline in patients with Alzheimer’s disease
Troussière, Anne-Cécile,
Monaca Charley, Christelle,
Salleron, Julia,
Richard, Florence,
Delbeuck, Xavier,
Derambure, Philippe,
Pasquier, Florence,
Bombois, Stéphanie
Background: It is essential to detect and then treat factors that aggravate Alzheimer’s disease (AD). Here, we sought to determine whether or not continuous positive airway pressure (CPAP) therapy for sleep apnoea syndrome (SAS) slows the rate of cognitive decline in mild-to-moderate AD patients.; Methods: Between January 2003 and June 2011, we included consecutive, mild-to-moderate […]